Power System Dynamic Simulations Using a Parallel Two-Level Schur-Complement Decomposition

As the need for faster power system dynamic simulations increases, it is essential to develop new algorithms that exploit parallel computing to accelerate those simulations. This paper proposes a parallel algorithm based on a two-level, Schur-complement-based, domain decomposition method. The two-level partitioning provides high parallelization potential (coarse- and fine-grained). In addition, due to the Schur-complement approach used to update the sub-domain interface variables, the algorithm exhibits high global convergence rate. Finally, it provides significant numerical and computational acceleration. The algorithm is implemented using the shared-memory parallel programming model, targeting inexpensive multi-core machines. Its performance is reported on a real system as well as on a large test system combining transmission and distribution networks

Dynamic simulation of large-scale power systems using a parallel schur-complement-based decomposition method

Power system dynamic simulations are crucial for the operation of electric power systems as they provide important information on the dynamic evolution of the system after an occurring disturbance. This paper proposes a robust, accurate and efficient parallel algorithm based on the Schur complement domain decomposition method. The algorithm provides numerical and computational acceleration of the procedure. Based on the shared-memory parallel programming model, a parallel implementation of the proposed algorithm is presented. The implementation is general, portable and scalable on inexpensive, shared-memory, multi-core machines. Two realistic test systems, a medium-scale and a large-scale, are used for performance evaluation of the proposed method

Contribution of distribution network control to voltage stability: A case study

A case study dealing with long-term voltage instability in systems hosting active distribution networks (DN) is reported in this paper. It anticipates future situations with high penetration of dispersed generation (DG), where the latter are used to keep distribution voltages within desired limits, in complement to load tap changers. The interactions between transmission and active DN are investigated on a 3108-bus test system. It involves transmission grid, large generators, and 40 DN, each with DG steered by a controller inspired by model predictive control. The reported simulations show the impact of distribution network voltage restoration, as well as the benefit of load voltage reduction actuated by the dispersed generators

Bispectral index is a topographically dependent variable in patients receiving propofol anaesthesia

Background. As very strong agreement has been reported between bispectral index (BIS) values measured from the occipital and frontal skull areas, we compared BIS values measured from central and parietal areas with those from frontal area to investigate whether BIS is really a topographically dependent or topographically independent variable. Methods. Twenty patients, ASA I-II, non-obese, aged 18-62 yr and with no neurological disorders were enrolled. Based on the 10-20 international landmarks, five silver dome electrodes were positioned: F7, C3, P7, Cz (common reference) and Fp1 (ground). Using frontal (F7-Cz), central (C3-Cz) and parietal (P7-Cz) electrode montages, the corresponding BIS values were simultaneously recorded with an Aspect A-1000 monitor (software v3.12). The BIS values were recorded at the propofol concentration allowing laryngeal mask insertion, which was maintained during the 10 min data collection period in absence of additional external stimuli. Data were analysed using the Kruskall-Wallis, Wilcoxon paired sign with Bonferroni correction, Bland-Altman and linear correlation tests. Results. At the predicted effect target propofol concentration 4-8 μg ml−1, the 10 min mean BIS (median [min-max]) were 32 [20-44], 46 [28-68] and 58 [41-72] for the frontal, central and parietal leads, respectively. Differences between these BIS recordings were statistically significant (P<0.0001, Kruskall-Wallis; P<0.005, Wilcoxon paired sign test). Conclusions. The present results provide evidence that BIS index is a topographically dependent variable in patients receiving propofol anaesthesi

Active Management of Low-Voltage Networks for Mitigating Overvoltages Due to Photovoltaic Units

In this paper, the overvoltage problems that might arise from the integration of photovoltaic (PV) panels into low-voltage (LV) distribution networks is addressed. A distributed scheme is proposed that adjusts the reactive and active power output of inverters to prevent or alleviate such problems. The proposed scheme is model-free and makes use of limited communication between the controllers in the form of a distress signal only during emergency conditions. It prioritizes the use of reactive power, while active power curtailment is performed only as a last resort. The behavior of the scheme is studied using dynamic simulations on a single LV feeder and on a larger network composed of 14 LV feeders. Its performance is compared with a centralized scheme based on the solution of an optimal power flow (OPF) problem, whose objective function is to minimize the active power curtailment. The proposed scheme successfully mitigates overvoltage situations due to high PV penetration and performs almost as well as the OPF-based solution with significantly less information and communication requirements

Co-Simulation of Electromagnetic Transients and Phasor Models: A Relaxation Approach

Co-simulation opens new opportunities to combine mature electromagnetic transients (EMT) and phasor-mode (PM) solvers, and takes advantage of their respective high accuracy and execution speed. In this paper, a relaxation approach is presented, iterating between an EMT and a PM solver. This entails interpolating over time the phasors of the PM simulation, extracting phasors from the time evolutions of the EMT simulation, and representing each subsystem with a proper multiport equivalent when simulating the other subsystem. Various equivalents are reviewed and compared in terms of convergence of the PM-EMT iterations. The paper also considers the update with frequency of the Thévenin impedances involved in the EMT simulation, the possibility to compute the EMT solution only once per time step, and the acceleration of convergence through a prediction over time of the boundary variables. Results are presented on a 74-bus, 23-machine test system, split into one EMT and one PM subsystem with several interface buses

A relaxation scheme to combine Phasor-Mode and Electromagnetic Transients Simulations

This paper deals with a new scheme for coupling phasor-mode and electromagnetic transients simulations. In each simulation, an iteratively updated linear equivalent is used to represent the effect of the subsystem treated by the other simulation. Time interpolation and phasor extraction methods adapted to this scheme are presented and compared to existing methods. Finally, simulation results obtained with a 74-bus test system are reporte

A Parallel Processing Approach to Dynamic Simulations of Combined Transmission and Distribution Systems

Simulating a power system with both transmission and distribution networks modeled in detail is a huge computational challenge. In this paper, a Schur-complement-based domain decomposition algorithm is proposed to provide accurate, detailed dynamic simulations of the combined system. The simulation procedure is accelerated with the use of parallel programming techniques, taking advantage of the parallelization opportunities inherent to domain decomposition algorithms. The proposed algorithm is general, portable and scalable on inexpensive, shared-memory, multi-core machines. A large-scale test system is used for its performance evaluation

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.

BackgroundCabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-type cohorts.Patients and methodsEligible patients had Child-Pugh A liver function and ≤1 prior systemic anticancer regimen, completed ≥4 weeks before study entry. The cabozantinib starting dose was 100 mg daily. After an initial 12-week cabozantinib treatment period, patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 were randomized to cabozantinib or placebo. The primary endpoint of the lead-in stage was objective response rate (ORR) at week 12, and the primary endpoint of the randomized stage was progression-free survival (PFS).ResultsAmong the 41 HCC patients enrolled, the week 12 ORR was 5%, with 2 patients achieving a confirmed partial response (PR). The week 12 disease control rate (PR or SD) was 66% (Asian subgroup: 73%). Of patients with ≥1 post-baseline scan, 78% had tumor regression, with no apparent relationship to prior sorafenib therapy. Alpha-fetoprotein (AFP) response (&gt;50% reduction from baseline) occurred in 9 of the 26 (35%) patients with elevated baseline AFP and ≥1 post-baseline measurement. Twenty-two patients with SD at week 12 were randomized. Median PFS after randomization was 2.5 months with cabozantinib and 1.4 months with placebo, although this difference was not statistically significant. Median PFS and overall survival from Day 1 in all patients were 5.2 and 11.5 months, respectively. The most common grade 3/4 adverse events, regardless of attribution, were diarrhea (20%), hand-foot syndrome (15%), and thrombocytopenia (15%). Dose reductions were utilized in 59% of patients.ConclusionsCabozantinib has clinical activity in HCC patients, including objective tumor responses, disease stabilization, and reductions in AFP. Adverse events were managed with dose reductions.Trial registration numberNCT00940225

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study

Adverse events; Cetuximab; EncorafenibEventos adversos; Cetuximab; EncorafenibEsdeveniments adversos; Cetuximab; EncorafenibColorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer (mCRC). Patients with BRAF V600E mutations, which occur in ∼10%-15% of patients with mCRC, have a poorer prognosis compared with those with wild-type BRAF tumours. The combination of the BRAF inhibitor encorafenib with the epidermal growth factor receptor inhibitor cetuximab currently represents the only chemotherapy-free targeted therapy approved in the USA and Europe for previously treated patients with BRAF V600E-mutated mCRC. As a class, BRAF inhibitors are associated with dermatologic, gastrointestinal, and renal events, as well as pyrexia and secondary skin malignancies. Adverse event (AE) profiles of specific BRAF inhibitors vary, however, and are affected by the specific agents given in combination. In patients with mCRC, commonly reported AEs of cetuximab monotherapy include infusion reactions and dermatologic toxicities. Data from the phase III BEACON CRC study indicate that the combination of encorafenib with cetuximab has a distinct safety profile. Here we review the most frequently reported AEs that occurred with this combination in BEACON CRC and best practices for managing and mitigating AEs that require more than standard supportive care.This work was supported by Array BioPharma in collaboration with Merck KGaA Darmstadt, Germany (for sites outside of North America), ONO Pharmaceutical, Japan, and Pierre Fabre, France. Array BioPharma was acquired by Pfizer in July 2019. This work was also supported by the Cancer Center Core [grant number P30 CA 008748] to MSKCC. Medical writing/editorial support was provided by Namiko Abe, PhD, and Alyson Bexfield, PhD, of Caudex, New York, and was funded by Pfizer